CytomX/CTMX

$1.80

-3.23%
-
1D1W1MYTD1YMAX

About CytomX

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated biologics designed to be localized to the tumor microenvironment. It is advancing potential first-in-class and best-in-class antibody-based therapeutics created using its PROBODY therapeutic technology platform. Its pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (ADCs), T-cell engagers, and immune modulators such as cytokines. Its clinical-stage pipeline includes CX-904, CX-2051 and CX-801. CX-904 is a conditionally activated T-cell-engaging antibody targeting the epidermal growth factor receptor on tumor cells and the CD3 receptor on T cells and partnered with Amgen in a global co-development alliance. CX-2051 is a conditionally activated ADC directed toward epithelial cell adhesion molecule (EpCAM) with potential applicability across multiple EpCAM-expressing epithelial cancers.

Ticker

CTMX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Sean Mccarthy

Employees

120

Headquarters

South san francisco, United States
Website
cytomx.com

CytomX Metrics

BasicAdvanced
$133.43M
Market cap
-
P/E ratio
-$0.02
EPS
1.04
Beta
-
Dividend rate
$133.43M
1.03697
$2.86
$1.04
921.12K
1.173
-53.626
-0.25%
-0.74%
1.318
197.81%
98.94%
0.28%

What the Analysts think about CytomX

Analyst Ratings

Majority rating from 7 analysts.
Hold

Price Targets

Average projection from 5 analysts.
61.11% upside
High $3.50
Low $2.25
$1.80
Current price
$2.90
Average price target

CytomX Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
3% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$26.6M
1.14%
Net income
$800K
-72.41%
Profit margin
3%
-72.78%

CytomX Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 135%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.05
-$0.02
$0.04
$0.01
-
Expected
-$0.11
-$0.21
-$0.19
-$0.03
-$0.05
Surprise
-52.72%
-90.24%
-121.18%
-135%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for CytomX stock?

CytomX (CTMX) has a market cap of $133.43M as of April 17, 2024.

What is the P/E ratio for CytomX stock?

The price to earnings (P/E) ratio for CytomX (CTMX) stock is 0 as of April 17, 2024.

Does CytomX stock pay dividends?

No, CytomX (CTMX) stock does not pay dividends to its shareholders as of April 17, 2024.

When is the next CytomX dividend payment date?

CytomX (CTMX) stock does not pay dividends to its shareholders.

What is the beta indicator for CytomX?

CytomX (CTMX) has a beta rating of 1.04. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the CytomX stock price target?

The target price for CytomX (CTMX) stock is $2.9, which is 61.11% above the current price of $1.8. This is an average based on projections from 5 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell CytomX stock

Buy or sell CytomX stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing